BG Medicine Fails to Regain Nasdaq Listing Compliance | GenomeWeb

NEW YORK (GenomeWeb News) – Nasdaq has notified BG Medicine that the company has not regained compliance with a listing requirement calling for at least $50 million in market value of its listed securities for continued listing on the exchange, BG Medicine said in a regulatory document.

In the document filed with the US Securities and Exchange Commission on Friday, the company said that it received written notice from Nasdaq's staff of the listing qualifications department on Nov. 14. As a result of the finding, BG Medicine may be delisted from Nasdaq.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.